NCT06510582View on ClinicalTrials.gov

Chronic Subdural Hematoma Treatment With Intra-Arterial Bevacizumab Injection

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

140

Participants

Timeline

Start Date

June 17, 2024

Primary Completion Date

June 30, 2028

Study Completion Date

June 30, 2028

Conditions
Chronic Subdural Hematoma
Interventions
DRUG

Bevacizumab 2 mg/kg

Single 2mg/kg dose of bevacizumab to treat unilateral cSDH

DRUG

Bevacizumab 4 mg/kg

Two 2mg/kg doses (cumulatively 4mg/kg) of bevacizumab to treat bilateral cSDH

Trial Locations (1)

08103

RECRUITING

Cooper University Health Care, Camden

All Listed Sponsors
collaborator

Society of Vascular and Interventional Neurology

UNKNOWN

lead

The Cooper Health System

OTHER